Metastatic/Recurrent

NRG CC014 (XRT at MBMC Only)

Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

---

EAQ222CD ***NON-METASTATIC COHORT CLOSED TO ACCRUAL EFFECTIVE 1/13/26****

Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients

---

A172401 (WF2304-A172401)

Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

---

EAY191-E5 **COHORT 1 CLOSED TO ACCRUAL EFFECTIVE SEPTEMBER 12, 2025** (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)

A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

---

S1501 (Required ECHO’s to be done at MBMC Only) **Arms 1 & 2 are permanently closed to accrual. Only Arm 3 (observation, non-randomized) remains open.**

Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

---

URCC 19185

Multicenter Randomized Controlled Trial comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)

---

EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**

Molecular Analysis for Combination Therapy Choice

---

S2013: I-CHECKIT ***Only Cohort 2 is open to enrollment***

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

---

S1703

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

---